Deutsch English Français

Contact

EP2809773

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2809773

EP2809773 - PROCESS OF MODULATING MAN5 AND/OR AFUCOSYLATION CONTENT OF GLYCOPROTEIN COMPOSITION [Right-click to bookmark this link]
Status	Patent revoked Status updated on 13.01.2023 Database last updated on 24.08.2024
Former	The patent has been granted Status updated on 31.07.2020
Former	Grant of patent is intended Status updated on 01.04.2020
Former	Examination is in progress Status updated on 14.11.2016
Most recent event Tooltip	27.04.2024	Lapse of the patent in a contracting state New state(s): MK	published on 29.05.2024 [2024/22]
Applicant(s)	For all designated states Dr. Reddy's Laboratories Limited Biologics Development Center Survey 47 Bachupalli Qutubullapur, RR District 500 090 / IN
	[2014/50]
Inventor(s)	01 / THUDUPPATHY, Guruvasuthevan Ramasamy 30A Thirumoorthy Layout Thadagam Road R S Puram Coimbatore 641002 / IN
	02 / MADHAVA RAM, Paranandi Ananta Flat 210 A1 Block Hema Durga Towers Miyapur Hyderabad 500049 / IN
	03 / BHAVSAR, Kaumil 6, Laxminagar Society Part-1 Opp. D.K. Patel Hall Naranpura Ahmedabad 380013 / IN
	04 / GARG, Neha Kothi No. 49 Sector 9 Urban Estate Behind New Grain (Anaj) Market Ambala 134003 / IN
	[2020/36]
Former [2014/50]	01 / THUDUPPATHY, Guruvasuthevan Ramasamy 30A Thirumoorthy Layout Thadagam Road R S Puram Coimbatore 641002 / IN
	02 / MADHAVA RAM, Paranandi Ananta Flat 210 A1 Block Hema Durga Towers Miyapur Hyderabad 500049 / IN
	03 / BHAVSAR, Kaumil 6 Laxminagar Society Part-1 Opp. D.K. Patel Hall Naranpura Ahmedabad 380013 / IN
	04 / GARG, Neha Kothi No. 49 Sector 9 Urban Estate Behind New Grain (Anaj) Market Ambala 134003 / IN
Representative(s)	Bates, Philip Ian Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS / GB
	[2020/36]
Former [2014/50]	Bates, Philip Ian Reddie & Grose LLP 16 Theobalds Road London WC1X 8PL / GB
Application number, filing date	13743691.1	18.01.2013
	[2020/36]
	WO2013IB50485
Priority number, date	IN2012CHE334	30.01.2012 Original published format: IN 334CH2012
	[2017/16]
Former [2014/50]	IN2012CHE0334	30.01.2012
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2013114245
	Date:	08.08.2013
	Language:	EN
	[2013/32]
	Type:	A1 Application with search report
	No.:	EP2809773
	Date:	10.12.2014
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 08.08.2013 takes the place of the publication of the European patent application.
	[2014/50]
	Type:	B1 Patent specification
	No.:	EP2809773
	Date:	02.09.2020
	Language:	EN
	[2020/36]
Search report(s)	International search report - published on:	CN	08.08.2013
	(Supplementary) European search report - dispatched on:	EP	23.06.2015
Classification	IPC:	C12N1/38, C12N15/13, C12P21/08, C07K16/00, A61K39/395, A61K39/40, A61K39/42, A61K39/44, A61K51/10, A61P37/04	[2014/50]
	CPC:	C12N5/0018 (EP,US); C07K16/2863 (US); A61P37/04 (EP); C07K16/32 (EP,US); C12N1/38 (EP,US); C12P21/005 (EP,US); (+) C07K2317/14 (US); C07K2317/41 (US); C12N2500/20 (EP,US); C12N2500/34 (EP,US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/50]
Extension states	BA	Not yet paid
	ME	Not yet paid
Title	German:	VERFAHREN ZUR MODULATION DES MAN5-UND/ODER AFUCOSYLATIONSGEHALTS EINER GLYCOPROTEINZUSAMMENSETZUNG	[2014/50]
	English:	PROCESS OF MODULATING MAN5 AND/OR AFUCOSYLATION CONTENT OF GLYCOPROTEIN COMPOSITION	[2014/50]
	French:	PROCÉDÉ DE MODULATION DE MAN5 ET/OU DU TAUX D'AFUCOSYLATION D'UNE COMPOSITION DE GLYCOPROTÉINE	[2014/50]
Entry into regional phase	07.08.2014	National basic fee paid
	07.08.2014	Search fee paid
	07.08.2014	Designation fee(s) paid
	07.08.2014	Examination fee paid
Examination procedure	07.08.2014	Examination requested [2014/50]
	06.01.2016	Amendment by applicant (claims and/or description)
	30.06.2016	Despatch of a communication from the examining division (Time limit: M06)
	20.12.2016	Reply to a communication from the examining division
	17.10.2017	Despatch of a communication from the examining division (Time limit: M06)
	29.03.2018	Reply to a communication from the examining division
	18.02.2019	Despatch of a communication from the examining division (Time limit: M04)
	13.06.2019	Reply to a communication from the examining division
	09.08.2019	Despatch of a communication from the examining division (Time limit: M02)
	17.10.2019	Reply to a communication from the examining division
	02.04.2020	Communication of intention to grant the patent
	23.07.2020	Fee for grant paid
	23.07.2020	Fee for publishing/printing paid
	23.07.2020	Receipt of the translation of the claim(s)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 30.06.2016
Opposition(s)	Opponent(s)	01 01.06.2021 07.06.2021 ADMISSIBLE Maiwald GmbH Elisenhof, Elisenstrasse 3 80335 München / DE Opponent's representative Maiwald GmbH Elisenhof Elisenstraße 3 80335 München / DE
		02 02.06.2021 07.06.2021 ADMISSIBLE STRAWMAN LIMITED Orchard Lea Horns Lane Combe Witney, Oxfordshire OX29 8NH / GB Opponent's representative Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB
		03 02.06.2021 07.06.2021 ADMISSIBLE Oetke, Cornelia Wallinger Ricker Schlotter Tostmann Zweibrückenstraße 5-7 80331 München / DE Opponent's representative Wallinger Ricker Schlotter Tostmann Patent- und Rechtsanwälte mbB Zweibrückenstraße 5-7 80331 München / DE
		04 02.06.2021 07.06.2021 ADMISSIBLE Breuer, Markus Brienner Straße 1 80333 München / DE Opponent's representative Breuer Friedrich Hahner Patentanwälte PartG mbB Brienner Straße 1 80333 München / DE
		05 02.06.2021 07.06.2021 ADMISSIBLE D Young & Co LLP 120 Holborn London EC1N 2DY / GB Opponent's representative D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB
		[N/P]
	Former [2021/28]
	Opponent(s)	01 01.06.2021 07.06.2021 ADMISSIBLE Maiwald Patent- und Rechtsanwaltsgesellschaft mbH Elisenhof, Elisenstrasse 3 80335 München / DE Opponent's representative Maiwald Patent- und Rechtsanwaltsgesellschaft mbH Elisenhof Elisenstraße 3 80335 München / DE
		02 02.06.2021 07.06.2021 ADMISSIBLE STRAWMAN LIMITED Orchard Lea Horns Lane Combe Witney, Oxfordshire OX29 8NH / GB Opponent's representative Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB
		03 02.06.2021 07.06.2021 ADMISSIBLE Oetke, Cornelia Wallinger Ricker Schlotter Tostmann Zweibrückenstraße 5-7 80331 München / DE Opponent's representative Wallinger Ricker Schlotter Tostmann Patent- und Rechtsanwälte mbB Zweibrückenstraße 5-7 80331 München / DE
		04 02.06.2021 07.06.2021 ADMISSIBLE Breuer, Markus Brienner Straße 1 80333 München / DE Opponent's representative Breuer Friedrich Hahner Patentanwälte PartG mbB Brienner Straße 1 80333 München / DE
		05 02.06.2021 07.06.2021 ADMISSIBLE D Young & Co LLP 120 Holborn London EC1N 2DY / GB Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
	Former [2021/27]
	Opponent(s)	01 01.06.2021 Maiwald Patent- und Rechtsanwaltsgesellschaft mbH Elisenhof, Elisenstrasse 3 80335 München / DE Opponent's representative Maiwald Patent- und Rechtsanwaltsgesellschaft mbH Elisenhof Elisenstraße 3 80335 München / DE
	15.06.2021	Invitation to proprietor to file observations on the notice of opposition
	30.09.2022	Despatch of communication that the patent will be revoked
	10.10.2022	Legal effect of revocation of patent [2023/07]
Fees paid	Renewal fee
	10.11.2014	Renewal fee patent year 03
	06.01.2016	Renewal fee patent year 04
	20.01.2017	Renewal fee patent year 05
	18.01.2018	Renewal fee patent year 06
	06.12.2018	Renewal fee patent year 07
	02.12.2019	Renewal fee patent year 08
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	18.01.2013
	AL	02.09.2020
	AT	02.09.2020
	CY	02.09.2020
	CZ	02.09.2020
	DK	02.09.2020
	EE	02.09.2020
	ES	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	IT	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	MC	02.09.2020
	MK	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SI	02.09.2020
	SK	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	IS	02.01.2021
	PT	04.01.2021
	IE	18.01.2021
	LU	18.01.2021
	BE	31.01.2021
	CH	31.01.2021
	LI	31.01.2021
	GB	18.01.2022
	FR	31.01.2022
	DE	02.08.2022
	[2024/22]
Former [2023/30]	HU	18.01.2013
	AL	02.09.2020
	AT	02.09.2020
	CY	02.09.2020
	CZ	02.09.2020
	DK	02.09.2020
	EE	02.09.2020
	ES	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	IT	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	MC	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SI	02.09.2020
	SK	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	IS	02.01.2021
	PT	04.01.2021
	IE	18.01.2021
	LU	18.01.2021
	BE	31.01.2021
	CH	31.01.2021
	LI	31.01.2021
	GB	18.01.2022
	FR	31.01.2022
	DE	02.08.2022
Former [2023/27]	HU	18.01.2013
	AL	02.09.2020
	AT	02.09.2020
	CZ	02.09.2020
	DK	02.09.2020
	EE	02.09.2020
	ES	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	IT	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	MC	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SI	02.09.2020
	SK	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	IS	02.01.2021
	PT	04.01.2021
	IE	18.01.2021
	LU	18.01.2021
	BE	31.01.2021
	CH	31.01.2021
	LI	31.01.2021
	GB	18.01.2022
	FR	31.01.2022
	DE	02.08.2022
Former [2022/50]	AL	02.09.2020
	AT	02.09.2020
	CZ	02.09.2020
	DK	02.09.2020
	EE	02.09.2020
	ES	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	IT	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	MC	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SI	02.09.2020
	SK	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	IS	02.01.2021
	PT	04.01.2021
	IE	18.01.2021
	LU	18.01.2021
	BE	31.01.2021
	CH	31.01.2021
	LI	31.01.2021
	GB	18.01.2022
	FR	31.01.2022
	DE	02.08.2022
Former [2022/47]	AL	02.09.2020
	AT	02.09.2020
	CZ	02.09.2020
	DK	02.09.2020
	EE	02.09.2020
	ES	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	IT	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	MC	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SI	02.09.2020
	SK	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	IS	02.01.2021
	PT	04.01.2021
	IE	18.01.2021
	LU	18.01.2021
	BE	31.01.2021
	CH	31.01.2021
	LI	31.01.2021
	GB	18.01.2022
	DE	02.08.2022
Former [2022/34]	AL	02.09.2020
	AT	02.09.2020
	CZ	02.09.2020
	DK	02.09.2020
	EE	02.09.2020
	ES	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	IT	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	MC	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SI	02.09.2020
	SK	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	IS	02.01.2021
	PT	04.01.2021
	IE	18.01.2021
	LU	18.01.2021
	BE	31.01.2021
	CH	31.01.2021
	LI	31.01.2021
Former [2022/07]	AL	02.09.2020
	AT	02.09.2020
	CZ	02.09.2020
	DK	02.09.2020
	EE	02.09.2020
	ES	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	IT	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	MC	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SI	02.09.2020
	SK	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	IS	02.01.2021
	PT	04.01.2021
	IE	18.01.2021
	LU	18.01.2021
	CH	31.01.2021
	LI	31.01.2021
Former [2021/52]	AL	02.09.2020
	AT	02.09.2020
	CZ	02.09.2020
	DK	02.09.2020
	EE	02.09.2020
	ES	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	IT	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	MC	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SI	02.09.2020
	SK	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	IS	02.01.2021
	PT	04.01.2021
	LU	18.01.2021
	CH	31.01.2021
	LI	31.01.2021
Former [2021/48]	AL	02.09.2020
	AT	02.09.2020
	CZ	02.09.2020
	DK	02.09.2020
	EE	02.09.2020
	ES	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	IT	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	MC	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SI	02.09.2020
	SK	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	IS	02.01.2021
	PT	04.01.2021
	LU	18.01.2021
Former [2021/43]	AL	02.09.2020
	AT	02.09.2020
	CZ	02.09.2020
	DK	02.09.2020
	EE	02.09.2020
	ES	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	MC	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SI	02.09.2020
	SK	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	IS	02.01.2021
	PT	04.01.2021
	LU	18.01.2021
Former [2021/40]	AL	02.09.2020
	AT	02.09.2020
	CZ	02.09.2020
	DK	02.09.2020
	EE	02.09.2020
	ES	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	MC	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SI	02.09.2020
	SK	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	IS	02.01.2021
	PT	04.01.2021
Former [2021/37]	AL	02.09.2020
	AT	02.09.2020
	CZ	02.09.2020
	DK	02.09.2020
	EE	02.09.2020
	ES	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SI	02.09.2020
	SK	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	IS	02.01.2021
	PT	04.01.2021
Former [2021/36]	AL	02.09.2020
	AT	02.09.2020
	CZ	02.09.2020
	EE	02.09.2020
	ES	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SI	02.09.2020
	SK	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	IS	02.01.2021
	PT	04.01.2021
Former [2021/28]	AL	02.09.2020
	AT	02.09.2020
	CZ	02.09.2020
	EE	02.09.2020
	ES	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SK	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	IS	02.01.2021
	PT	04.01.2021
Former [2021/25]	AL	02.09.2020
	AT	02.09.2020
	CZ	02.09.2020
	EE	02.09.2020
	ES	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	IS	02.01.2021
	PT	04.01.2021
Former [2021/24]	AT	02.09.2020
	CZ	02.09.2020
	EE	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	PT	04.01.2021
Former [2021/23]	CZ	02.09.2020
	EE	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	SM	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	PT	04.01.2021
Former [2021/22]	CZ	02.09.2020
	EE	02.09.2020
	FI	02.09.2020
	HR	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RO	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	PT	04.01.2021
Former [2021/21]	FI	02.09.2020
	HR	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
	PT	04.01.2021
Former [2021/18]	FI	02.09.2020
	HR	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	NL	02.09.2020
	PL	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
Former [2021/10]	FI	02.09.2020
	HR	02.09.2020
	LT	02.09.2020
	LV	02.09.2020
	PL	02.09.2020
	RS	02.09.2020
	SE	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
Former [2021/09]	FI	02.09.2020
	LT	02.09.2020
	SE	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
	GR	03.12.2020
Former [2021/08]	FI	02.09.2020
	LT	02.09.2020
	SE	02.09.2020
	BG	02.12.2020
	NO	02.12.2020
Former [2021/07]	FI	02.09.2020
	LT	02.09.2020
	NO	02.12.2020
Documents cited:	Search	[XI]WO2011019622 (GENENTECH INC [US], et al) [X] 1,3-11 * abstract * * page 2, lines 16-18 * * page 3, line 26 - page 5, line 4 * * page 6, lines 18-19 * * page 38, line 20 - page 39, line 24 * [I] 12,13;
		[XI]WO2011127322 (MOMENTA PHARMACEUTICALS INC [US], et al) [X] 1-6 * abstract * * paragraphs [0002] , [0015] , [0018] , [0021] , [0041] - [0045] - [0048] , [0065] , [0066] * * example 4 *[I] 7-13
	International search	[A]WO2007070315 (AMGEN INC [US], et al);
		[A]US2011053223 (BAYER ROBERT [US], et al);
		[X] - PACIS E. ET AL., "Effects of cell culture conditions on antibody N-linked glycosylation -- what affects high mannose 5 glycoform", BIOTECHNOLOGY AND BIOENGINEERING, (20111010), vol. 108, no. 10, pages 2348 - 2358, XP055080567 DOI: http://dx.doi.org/10.1002/bit.23200
		[Y] - YAMANE O. ET AL., "Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity", BIOTECHNOLOGY AND BIOENGINEERING, (20040905), vol. 87, no. 5, pages 614 - 622, XP002983153 DOI: http://dx.doi.org/10.1002/bit.20151
		[Y] - KATSUHIRO M. ET AL., "Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA", BIOTECHNOLOGY AND BIOENGINEERING, (20041230), vol. 88, no. 7, pages 901 - 908, XP002361932 DOI: http://dx.doi.org/10.1002/bit.20326
	by applicant	US5821337
		WO2011019622
		US2011053223
		US7972810
		WO2011127322
		- MARINO, K., Nature Chemical Biology, (20100000), vol. 6, pages 713 - 723
		- SCHWARZ, F.AEBI M., Current Opinion in Structural Biology, (20110000), vol. 21, pages 576 - 582
		- BURDA, P.AEBI M., Biochimica et Biophysica Acta (BBA) General Subjects, (19990000), vol. 1426, no. 2, pages 239 - 257
		- HANRUE IMAI-NISHIYA, BMC Biotechnology, (20070000), vol. 7, page 84
		- KAUFMAN, H.MAZUR X.FUSSENEGGER, M.BAILEY, J.E., Biotechnol Bioeng., (19990000), vol. 63, pages 573 - 578
		- TRUMMER, E.FAULAND, K., Biotechnol Bioeng., (20060000), vol. 94, pages 1045 - 1052
		- YOON S.K.SONG, J. Y.LEE, G.M., Biotechnol Bioeng., (20030000), vol. 82, pages 289 - 298
		- MOORE AMERCER JDUTINA GDONAHUE CJBAUER KDMATHER JPETCHEVERRY TRYLL T, Cytotechnology, (19970000), vol. 23, pages 47 - 54
		- BORYS M.C.LINZER, D.I.H., PAPOUTSAKIS, BIO/technology, (19930000), vol. 11, pages 720 - 724
		- MUTHING JKEMMINER SECONRADT HSSAGI DNIMTZ MKARST UPETER- KATALINIC J., Biotechnol Bioeng, (20030000), vol. 83, pages 321 - 334
		- CROWELL CKGRAMPP GEROGERS GNMILLER JSCHEINMAN RI., Biotechnol Bioeng., (20070000), vol. 96, pages 538 - 549
		- PACIS, E.YU, M.AUTSEN, J.BAYER, R.LI, F., Biotechnology and Bioengineering, (20110000), vol. 108, pages 2348 - 2358
		- WRIGHTMORRISON, J. Exp. Med., (19940000), vol. 180, pages 1087 - 1096
		- J.lmnnmology, (19980000), vol. 160, pages 3393 - 3402
		- ZHOU Q. et al., Biotechnol Bioeng, (20080000), vol. 99, no. 3, pages 652 - 665
		- MORI K, Cytotechnology, (20070000), vol. 55, no. 2-3, pages 109 - 114
		- SHIELDS RL, J Biol Chem, (20020000), vol. 277, no. 30, pages 26733 - 26740
		- WUHRER M. et al., Journal of Chromatography B, (20050000), vol. 825, no. 2, pages 124 - 133
		- RUHAAK L.R., Anal Bioanal Chem, (20100000), vol. 397, pages 3457 - 3481
		- GEOFFREY, R. G., Analytical Biochemistry, (19960000), vol. 240, pages 210 - 226
	Opposition	WO2007070315
		WO2008128227
		WO2010138502
		WO2010141855
		WO2011019622
		WO2011127322
		WO2012149197
		US6048728
		WO2011134919
		IN334CHE2012
		WO2008008360
		WO2013114245
		US5096816
		WO2008109410
		EP3434760
		- Christopher A. Sellick, "Optimizing CHO Cell Culture Conditions", (20091001), URL: https://www.genengnews.com/magazine/120/optimizing-cho-cell-culture-conditions/, (20201109), XP055748367
		- PACIS et al., "Effects of Cell Culture Conditions on Antibody N-linked Glycosylation - What Affects High Mannose 5 Glycoform", Biotechnol. Bioeng., (20110000), vol. 108, no. 1 0, doi:10.1002/bit.23200, pages 2348 - 2358, XP055080567 DOI: http://dx.doi.org/10.1002/bit.23200
		- GRAMER et al., "Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose", Biotechnol. Bioeng., (20110000), vol. 108, no. 7, doi:10.1002/bit.23075, pages 1591 - 1602, XP002688515 DOI: http://dx.doi.org/10.1002/bit.23075
		- CROWELL et al., "Amino Acid and Manganese Supplementation Modulates the Glycosylation State of Erythropoietin in a CHO Culture System", Biotechnol. Bioeng., (20060000), vol. 96, no. 3, doi:10.1002/bit.21141, pages 538 - 549, XP002457773 DOI: http://dx.doi.org/10.1002/bit.21141
		- GAWLITZEK et al., "Identification of Cell Culture Conditions to Control N-glycosylation Site-Occupancy of Recombinant Glycoproteins Expressed in CHO Cells", Biotechnol. Bioeng., (20090000), vol. 103, no. 6, doi:10.1002/BIT.22348, pages 1164 - 1175, XP002688571 DOI: http://dx.doi.org/10.1002/BIT.22348
		- SPEARMAN M. et al., "The role of glycosylation in therapeutic antibodies. In: Al-Rubeai M. (eds) Antibody Expression and Production", Cell Engineer- ing, (20110000), vol. 7, no. Chapter 12, pages 251 - 292, XP055240498
		- JENKINS N. et al., "Getting the glycosylation right: implications for the bio- technology industry", Nat Biotechnol., (19960000), vol. 14, pages 975 - 981, XP002133654 DOI: http://dx.doi.org/10.1038/nbt0896-975
		- RAJU T.S., "Glycosylation variations with expression systems and their im- pact on biological activity of therapeutic immunoglobulins", BioProcess In- ternational, (20030000), vol. 1, no. 4, pages 44 - 53, XP001247475
		- PACIS E. et al., "Effects of cell culture conditions on antibody N-linked gly- cosylation-what affects high mannose 5 glycoform", Biotechnol Bioeng., (20110000), vol. 108, pages 2348 - 2358, XP055080567 DOI: http://dx.doi.org/10.1002/bit.23200
		- GRAMER M.J. et al., "Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose", Biotechnol Bioeng., (20110000), vol. 108, doi:10.1002/bit.23075, pages 1591 - 602, XP002688515 DOI: http://dx.doi.org/10.1002/bit.23075
		- BIBILA T.A. et al., "In pursuit of the optimal fed-batch process for monoclonal antibody production", Biotechnol Prog, (19950000), vol. 11, no. 1, doi:10.1021/bp00031a001, pages 1 - 13, XP001183574 DOI: http://dx.doi.org/10.1021/bp00031a001
		- CROWELL C.K. et al., "Amino acid and manganese supplementation modu- lates the glycosylation state of erythropoietin in a CHO culture system", Biotechnol Bioeng., (20070000), vol. 96, no. 3, pages 538 - 549, XP002454615 DOI: http://dx.doi.org/10.1002/bit.21141
		- BURGENER A. et al., "Medium Development", Cell Culture Tech- nology for Pharmaceutical and Cell - Based Therapies, (20060000), pages 41 - 79, XP055454641
		- HOSSLER P. et al., "Optimal and consistent protein glycosylation in mamma- lian cell culture", Glycobiology, (20090000), vol. 19, no. 9, pages 936 - 949, XP055112498 DOI: http://dx.doi.org/10.1093/glycob/cwp079
		- P. Hossler, S. F Khattak, Z. J. Li, "Optimal and consistent protein glycosylation in mammalian cell culture", Glycobiology, Oxford University Press, (20090901), vol. 19, no. 9, doi:10.1093/glycob/cwp079, ISSN 09596658, pages 936 - 949, XP055112498 DOI: http://dx.doi.org/10.1093/glycob/cwp079
		- Martin Gawlitzek, Michael Estacio, Tobias Fürch, Robert Kiss, "Identification of cell culture conditions to control N-glycosylation site-occupancy of recombinant glycoproteins expressed in CHO cells.", Biotechnology and Bioengineering, John Wiley, Hoboken, USA, Hoboken, USA, (20090409), vol. 103, no. 6, doi:10.1002/BIT.22348, ISSN 0006-3592, pages 1164 - 1175, XP002688571 DOI: http://dx.doi.org/10.1002/BIT.22348
		- YAMANE-OHNUKI N. ET AL., "Establishment of FUT8 knockout chinese hanster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity", Biotechnology and Bioengineering, John Wiley, Hoboken, USA, Hoboken, USA, (20040806), vol. 87, no. 5, doi:10.1002/bit.20151, ISSN 0006-3592, pages 614 - 622, XP002983758 DOI: http://dx.doi.org/10.1002/bit.20151
		- Efren Pacis; Marcella Yu; Jennifer Autsen; Robert Bayer; Feng Li, "Effects of cell culture conditions on antibody N‐linked glycosylation—what affects high mannose 5 glycoform", Biotechnology and Bioengineering, John Wiley, Hoboken, USA, Hoboken, USA, (20110524), vol. 108, no. 10, doi:10.1002/bit.23200, ISSN 0006-3592, pages 2348 - 2358, XP071115329 DOI: http://dx.doi.org/10.1002/bit.23200
		- Michael J. Gramer; Jackie J. Eckblad; Ruth Donahue; Joseph Brown; Carrie Shultz; Kent Vickerman; Patrick Priem; Ewald T.J. van den Bremer; Jolanda Gerritsen; Patrick H.C. van Berkel, "Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose", Biotechnology and Bioengineering, John Wiley, Hoboken, USA, Hoboken, USA, (20110218), vol. 108, no. 7, doi:10.1002/bit.23075, ISSN 0006-3592, pages 1591 - 1602, XP071113776 DOI: http://dx.doi.org/10.1002/bit.23075
		- Christopher K. Crowell; Gustavo E. Grampp; Gary N. Rogers; Janis Miller; Robert I. Scheinman, "Amino acid and manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture system", Biotechnology and Bioengineering, John Wiley, Hoboken, USA, Hoboken, USA, (20060825), vol. 96, no. 3, doi:10.1002/bit.21141, ISSN 0006-3592, pages 538 - 549, XP071134465 DOI: http://dx.doi.org/10.1002/bit.21141
		- Katsuhiro Mori; Reiko Kuni‐Kamochi; Naoko Yamane‐Ohnuki; Masako Wakitani; Kazuya Yamano; Harue Imai; Yutaka Kanda; Rinpei Niwa; Shigeru Iida; Kazuhisa Uchida; Kenya Shitara; Mitsuo Satoh, "Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA", Biotechnology and Bioengineering, John Wiley, Hoboken, USA, Hoboken, USA, (20041028), vol. 88, no. 7, doi:10.1002/bit.20326, ISSN 0006-3592, pages 901 - 908, XP071151692 DOI: http://dx.doi.org/10.1002/bit.20326
		- A. M. Goetze, Y. D. Liu, Z. Zhang, B. Shah, E. Lee, P. V. Bondarenko, G. C. Flynn, "High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans", Glycobiology, Oxford University Press, (20110701), vol. 21, no. 7, doi:10.1093/glycob/cwr027, ISSN 09596658, pages 949 - 959, XP055169019 DOI: http://dx.doi.org/10.1093/glycob/cwr027
		- Anonymous, "Printout DMEM/F-12", Thermo Fisher Scientific, (20210530), no. 11320033, pages 1 - 3, XP055951806
		- Anonymous, "Mammalian Cell Biotechnology- A practical approach", IRL Press, (19910101), pages 8 - 15, XP055951810
		- ARATHOON W R, BIRCH J R, "LARGE-SCALE CELL CULTURE IN BIOTECHNOLOGY", Science, American Association for the Advancement of Science, US, US , (19860101), vol. 232, no. 4756, doi:10.1126/science.2424083, ISSN 0036-8075, pages 1390 - 1395, XP008032746 DOI: http://dx.doi.org/10.1126/science.2424083
		- Hauser Hansjorg, Wagner, "Mammalian cell biotechnology in protein production", RolandMammalian Cell Biotechnology in Protein Production, (19970101), pages 244 - 249, XP055951823
		- Anonymous, "Cytiva Hyclone CDM4CHO Media Liquid", Thermo Fisher datasheet, (20210530), pages 1 - 1, XP055951827
		- Surve Tanaya, Gadgil Mugdha, "Manganese increases high mannose glycoform on monoclonal antibody expressed in CHO when glucose is absent or limiting: Implications for use of alternate sugars", Biotechnology Progress, American Chemical Society, (20150301), vol. 31, no. 2, doi:10.1002/btpr.2029, ISSN 8756-7938, pages 460 - 467, XP055927999 DOI: http://dx.doi.org/10.1002/btpr.2029
		- Feng Li, Natarajan Vijayasankaran, Amy (yijuan) Shen, Robert Kiss, Ashraf Amanullah, "Cell culture processes for monoclonal antibody production", mAbs, (20100901), vol. 2, no. 5, doi:10.4161/mabs.2.5.12720, ISSN 19420862, pages 466 - 479, XP055166177 DOI: http://dx.doi.org/10.4161/mabs.2.5.12720
		- Gramer M J, Eckblad J J, Donahue R, Brown J, Shultz C, Vickerman K, Priem P, van den Bremer E T, Gerritsen J, van Berkel P H, "Modulation of Antibody Galactosylation Through Feeding of Uridine, Manganese Chloride, and Galactose", Biotechnology and Bioengineering, John Wiley, Hoboken, USA, Hoboken, USA, (20110701), vol. 108, no. 7, doi:10.1002/bit.23075, ISSN 0006-3592, pages 1591 - 1602, XP002688515 DOI: http://dx.doi.org/10.1002/bit.23075
		- RESTELLI V, BUTLER M, "THE EFFECT OF CELL CULTURE PARAMETERS ON PROTEIN GLYCOSYLATION", CELL ENGINEERING, XX, XX, XX , (20020101), vol. 03, pages 61 - 92, XP001203473
		- GONZALEZ DANIEL S ET AL, "Identification, expression, and characterization of a cDNA encoding human endoplasmic reticulum mannosidase I, the enzyme that catalyzes the first mannose trimming step in mammalian Asn-linked oligosaccharide biosynthesis.", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (19990723), vol. 274, no. 30, doi:10.1074/jbc.274.30.21375, ISSN 0021-9258, pages 21375 - 21386, XP002150706 DOI: http://dx.doi.org/10.1074/jbc.274.30.21375
		- KAMINSKA JOANNA, GLICK MARY CATHERINE, KOSCIELAK JERZY, "Purification and characterization of GDP-L-Fuc: N-acetyl beta-D-glucosaminide alpha1 leads to 6fucosyltransferase from human blood platelets", Glycoconjugate Journal, Chapman & Hall, Boston, Boston , (19980801), vol. 15, no. 8, doi:10.1023/A:1006959915435, ISSN 0282-0080, pages 783 - 788, XP002526140 DOI: http://dx.doi.org/10.1023/A:1006959915435
		- Patrick Hossler, "Protein Glycosylation Control in Mammalian Cell Culture: Past Precedents and Contemporary Prospects", Advances in Biochemical Engineering Biotechnology, Springer, Berlin, Heidelberg , (20120101), vol. 127, pages 187 - 219, doi:10.1007/10_2011_113, ISBN 978-3-642-28349-9, XP055679442 DOI: http://dx.doi.org/10.1007/10_2011_113
		- Kuystermans, Al- Rubeai, "Antibody expression and production", Cell Engineering, (20110101), vol. 7, doi:10.1007/978-94-007-1257-7, pages 42 - 52, XP055951856 DOI: http://dx.doi.org/10.1007/978-94-007-1257-7
		- Jong Hyun Nam, Fuming Zhang, Myriam Ermonval, Robert J. Linhardt, Susan T. Sharfstein, "The effects of culture conditions on the glycosylation of secreted human placental alkaline phosphatase produced in Chinese hamster ovary cells", Biotechnology and Bioengineering, Wiley ¬etc.\|, (20080815), vol. 100, no. 6, doi:10.1002/bit.21853, ISSN 00063592, pages 1178 - 1192, XP055053835 DOI: http://dx.doi.org/10.1002/bit.21853
		- Maria Elisa Rodrigues, Costa Ana Rita, Henriques Mariana, Azeredo Joana, Oliveira Rosã¡rio, "Technological progresses in monoclonal antibody production systems", Biotechnology Progress, American Chemical Society, (20091230), vol. 26, doi:10.1002/btpr.348, ISSN 87567938, pages 332 - 351, XP055117107 DOI: http://dx.doi.org/10.1002/btpr.348
		- BOLLATI-FOGOLIN MARIELA ET AL, "Temperature reduction in cultures of hGM-CSF-expressing CHO cells: Effect on productivity and product quality", Biotechnology Progress, American Chemical Society, (20050101), vol. 21, no. 1, doi:10.1021/bp049825t, ISSN 8756-7938, pages 17 - 21, XP002461348 DOI: http://dx.doi.org/10.1021/bp049825t
		- Efren Pacis, Marcella Yu, Jennifer Autsen, Robert Bayer, Feng Li, "Effects of cell culture conditions on antibody N-linked glycosylation-what affects high mannose 5 glycoform", Biotechnology and Bioengineering, Wiley ¬etc.\|, (20111001), vol. 108, no. 10, doi:10.1002/bit.23200, ISSN 00063592, pages 2348 - 2358, XP055080567 DOI: http://dx.doi.org/10.1002/bit.23200
		- Ying Quing Yu, Ahn Joomi, Gilar Martin, "Trastuzuman Glycan Batch-to-Batch Profiling using a UPLC/FLR/Mass Spectrometry Platform", United States, United States , (20100601), pages 1 - 8, URL: http://www.waters.com/webassets/cms/library/docs/720003576en.pdf, (20180207), XP055448715
		- Zhou Quin; Shankara Srinivas; Roy Andre; Qiu Huawei; Estes Scott; McVie-Wylie Alison; Culm-Merdek Kerry; Park Anna; Pan Clark; Edmunds, "Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function", Biotechnology and Bioengineering, John Wiley, Hoboken, USA, Hoboken, USA, (20080201), vol. 99, no. 3, doi:10.1002/bit.21598, ISSN 0006-3592, pages 652 - 665, XP009137262 DOI: http://dx.doi.org/10.1002/bit.21598
		- Tojo S, Okazaki A, Wakitani M, Shinkawa T, Uchida K, Suzawa T., "A chromatographic approach for elevating the antibody-dependent cellular cytotoxicity of antibody composites.", Biological & pharmaceutical bulletin, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO., JP, JP , (20090901), vol. 32, no. 9, doi:10.1248/bpb.32.1604 , ISSN 0918-6158, pages 1604 - 1608, XP002689095 DOI: http://dx.doi.org/10.1248/bpb.32.1604

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p